Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Express News | MacroGenics Shares Down 7.4% as Data Shows Worsening Safety Profile for Co's Prostate Cancer Drug
TD Cowen Maintains Macrogenics(MGNX.US) With Hold Rating
TD Cowen analyst Tara Bancroft maintains $Macrogenics(MGNX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 56.1% and a total average return of 21.8% over the
Stifel Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $6
Stifel analyst Stephen Willey maintains $Macrogenics(MGNX.US)$ with a hold rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 43.6% and a
Evercore Maintains Macrogenics(MGNX.US) With Buy Rating
Evercore analyst Jonathan Miller maintains $Macrogenics(MGNX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 20.0% and a total average return of -22.6% over the
Evercore ISI Sticks to Their Buy Rating for MacroGenics (MGNX)